Pharmacovigilance for a Revolving World: Prospects of Patient-Generated Data on the Internet

Drug Safety

Volumn 37, Issue 10, 2014, Pages 761-764

  Norén, G Niklas ^a,b  

^a UPPSALA MONITORING CENTRE   (Sweden)

^b STOCKHOLM UNIVERSITY   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

DRUG SURVEILLANCE PROGRAM; HUMAN; INFORMATION PROCESSING; INTERNET; PATIENT PARTICIPATION; PROCEDURES; UTILIZATION;

DATA COLLECTION; HUMANS; INTERNET; PATIENT PARTICIPATION; PHARMACOVIGILANCE;

EID: 84934270864     PISSN: 01145916     EISSN: 11791942     Source Type: Journal    
DOI: 10.1007/s40264-014-0205-4     Document Type: Editorial

References (21)

1. Basch E. The missing voice of patients in drug-safety reporting. N Engl J Med. 2010;362(10):865–9.
2. Banerjee A, Okun S, Edwards IR, et al. Patient-reported outcome measures in safety event reporting: PROSPER consortium guidance. Drug Saf. 2013;36(12):1129–49.
3. Wicks P, Vaughan TE, Massagli MP, Heywood J. Accelerated clinical discovery using self-reported patient data collected online and a patient-matching algorithm. Nat Biotech. 2011;29(5):411–4.
4. de Langen J, van Hunsel F, Passier A, den Berg L-V, van Grootheest K. Adverse drug reaction reporting by patients in The Netherlands: three years of experience. Drug Saf. 2008;31(6):515–24.
5. Bergvall T, Norén GN, Lindquist M. vigiGrade: a tool to identify well-documented individual case reports and highlight systematic data quality issues. Drug Saf. 2014;37(1):65–77.
6. Knezevic MZ, Bivolarevic IC, Peric TS, Jankovic SM. Using Facebook to increase spontaneous reporting of adverse drug reactions. Drug Saf. 2011;34(4):351–2.
7. Edwards IR, Lindquist M. Social media and networks in pharmacovigilance: boon or bane? Drug Saf. 2011;34(4):267–71.
8. Franzen W. Can social media benefit drug safety? Drug Saf. 2011;34(9):793.
9. Freifeld CC, Brownstein JS, Menone CM, et al. Digital drug safety surveillance: monitoring pharmaceutical products in Twitter. Drug Saf. 2014;37(5):343–50.
10. Chee BW, Berlin R, Schatz B. Predicting adverse drug events from personal health messages. AMIA Annu Symp Proc. 2011;2011:217–26.
11. White RW, Harpaz R, Shah NH, DuMouchel W, Horvitz E. Toward enhanced pharmacovigilance using patient-generated data on the internet. Clin Pharmacol Ther. 2014;96(2):239–46. doi:10.1038/clpt.2014.77.
12. White RW, Tatonetti NP, Shah NH, Altman RB, Horvitz E. Web-scale pharmacovigilance: listening to signals from the crowd. J Am Med Inform Assoc. 2013;20(3):404–8.
13. Norén GN, Hopstadius J, Bate A, Star K, Edwards IR. Temporal pattern discovery in longitudinal electronic patient records. Data Min Knowl Disc. 2010;20(3):361–87.
14. van Hunsel F, van der Welle C, Passier A, van Puijenbroek E, van Grootheest K. Motives for reporting adverse drug reactions by patient-reporters in The Netherlands. Eur J Clin Pharmacol. 2010;66(11):1143–50.
15. Grajales F, Clifford D, Loupos P, et al. Social networking sites and the continuously learning health system: a survey: Institute of Medicine; 23 Jan 2014.
16. Norén GN, Caster O, Juhlin K, Lindquist M. Zoo or Savannah? Choice of training ground for evidence-based pharmacovigilance. Drug Saf. Epub 9 Jul 2014. doi:10.1007/s40264-014-0198-z.
17. Lazer D, Kennedy R, King G, Vespignani A. The parable of Google Flu: traps in big data analysis. Science. 2014;343(6176):1203–5.
18. Edwards IR. What are the real lessons from Vioxx? Drug Saf. 2005;28(8):651–8.
19. Ginsberg J, Mohebbi MH, Patel RS, Brammer L, Smolinski MS, Brilliant L. Detecting influenza epidemics using search engine query data. Nature. 2009;457(7232):1012–4.
20. Lindquist M. VigiBase, the WHO Global ICSR Database System: basic facts. Drug Inf J. 2008;42(5):409–19.
21. Norén GN, Orre R, Bate A, Edwards IR. Duplicate detection in adverse drug reaction surveillance. Data Min Knowl Disc. 2007;14(3):305–28.